Effect of Sodium Thiosulfate on Cisplatin Removal With Complete Hepatic Venous Isolation and Extracorporeal Charcoal Hemoperfusion: A Pharmacokinetic Evaluation
暂无分享,去创建一个
Y. Ku | Y. Kuroda | M. Tominaga | T. Iwasaki | T. Fukumoto | S. Muramatsu | N. Kusunoki | Yasuyuki Suzuki | M. Takamatsu | S. Tsuchida | T. Sugimoto
[1] Y. Kuroda,et al. Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion. , 1998, Cancer research.
[2] E. Neuwelt,et al. First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. , 1998, The Journal of pharmacology and experimental therapeutics.
[3] Y. Kuroda,et al. Induction of long-term remission in advanced hepatocellular carcinoma with percutaneous isolated liver chemoperfusion. , 1998, Annals of surgery.
[4] Y. Kuroda,et al. Single catheter technique of hepatic venous isolation and extracorporeal charcoal hemoperfusion for malignant liver tumors. , 1997, American journal of surgery.
[5] Y. Kuroda,et al. Clinical pilot study on high-dose intraarterial chemotherapy with direct hemoperfusion under hepatic venous isolation in patients with advanced hepatocellular carcinoma. , 1995, Surgery.
[6] A. Gabizon,et al. Reduction of the systemic toxicity of cisplatin by intra‐arterial hepatic route administration for liver malignancies , 1995, International journal of cancer.
[7] T. Ravikumar,et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] O. Dalesio,et al. Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy--a phase II study of the EORTC Gynaecological Cancer Cooperative Group. , 1994, European journal of cancer.
[9] H. Malmström,et al. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer. , 1993, Gynecologic oncology.
[10] Y. Kuroda,et al. [Comparison of hepatic tissue extraction rates of cytotoxic anticancer drugs during hepatic arterial chemotherapy--evaluation using direct hemoperfusion under hepatic venous isolation]. , 1993, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.
[11] J. Lewis,et al. Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy. , 1991, Gynecologic oncology.
[12] M. Esposito,et al. Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases , 1991, Cancer.
[13] S. Curley,et al. Hepatic arterial infusion chemotherapy with complete hepatic venous isolation and extracorporeal chemofiltration: a feasibility study of a novel system , 1991, Anti-cancer drugs.
[14] H. Ohyanagi,et al. Extracorporeal removal of anticancer drugs in hepatic artery infusion: the effect of direct hemoperfusion combined with venovenous bypass. , 1990, Surgery.
[15] K. Masuhara,et al. High-performance liquid chromatographic analysis of unchanged cis-diamminedichloroplatinum (cisplatin) in plasma and urine with post-column derivatization. , 1990, Journal of chromatography.
[16] S. Howell,et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. , 1989, Journal of the National Cancer Institute.
[17] H. Ohyanagi,et al. [Extracorporeal adriamycin-removal following hepatic artery infusion: use of direct hemoperfusion combined with veno-venous bypass]. , 1989, Nihon Geka Gakkai zasshi.
[18] T. Akiyoshi,et al. 'Two-route chemotherapy' using intra-arterial cisplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies. , 1988, European journal of cancer & clinical oncology.
[19] H. Pinedo,et al. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. , 1986, Clinical chemistry.
[20] K. Wilms,et al. [Therapy of peritoneal carcinosis with intraperitoneal administration of cis-diamminedichloroplatinum and systemic sodium thiosulfate protection. Clinical results of a pilot study and pharmacokinetics]. , 1985, Onkologie.
[21] M. Hirano,et al. [Pharmacokinetics of cisplatin and the effect of sodium thiosulfate]. , 1984, Gan to kagaku ryoho. Cancer & chemotherapy.
[22] T. N. Campbell,et al. Clinical pharmacokinetics of intraarterial cisplatin in humans. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Olshen,et al. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. , 1983, Cancer research.
[24] A. Ivankovich,et al. Sodium Thiosulfate Disposition in Humans: Relation to Sodium Nitroprusside Toxicity , 1983, Anesthesiology.
[25] R. Olshen,et al. Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.
[26] S. Wallace,et al. Phase I‐II trial of percutaneous intra‐arterial Cis‐diamminedichloro platinum (II) for regionally confined malignancy , 1980, Cancer.
[27] A. Guarino,et al. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. , 1977, Biochemical medicine.